orthotw.com
/1 month ago
Peptide Growth Factor (P-15L) Beats Autograft in TLIF Trial
Two-hundred-ninety patients with degenerative were treated with either autograft or Cerapedics Inc.’s PearlMatrix P-15 Peptide Enhanced at 33 U.S. sites.